ClinicalTrials.gg
CompletedNCT06625840Updated Oct 3, 2024

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

A Phase 1 interventional study of MK-1167 and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 60 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Sep 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

The goal of this study is to learn how safe MK-1167 is in healthy elderly adults and how well people tolerate it.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The main inclusion criteria include but are not limited to the following:

  • Be in good health

The main exclusion criteria include but are not limited to the following:

  • History of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • History of cancer ().
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Panel A

    Participants receive a loading dose of MK-1167 or Placebo orally on day 1, followed by a once daily (QD) maintenance dose orally on days 2 to 16.

    Drug: MK-1167 · Drug: Placebo

  • Experimental
    Panel B

    Participants receive a loading dose of MK-1167 or Placebo orally on days 1 to 3, followed by a QD maintenance dose orally on days 4 to 16.

    Drug: MK-1167 · Drug: Placebo

Interventions

  • Oral Administration

  • DrugPlacebo

    Oral Administration

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Adverse Event (AE)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.

    Time frame: Up to approximately 41 days

  2. Number of Participants Discontinuing Study Treatment due to an AE

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.

    Time frame: Up to approximately 16 days

  3. Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-1167 after Multiple Doses

    Blood samples will be collected to determine the AUC0-24 of MK-1167.

    Time frame: Predose and at designated timepoints up to 24 hours postdose on days 1, 8 and 16

  4. Maximum Concentration (Cmax) of MK-1167 after Multiple Doses

    Blood samples will be collected to determine the Cmax of MK-1167.

    Time frame: Predose and at designated timepoints up to 24 hours postdose on days 1 and 8 and up to 600 hours postdose on day 16

  5. Concentration at 24 hours (C24) of MK-1167 after Multiple Doses

    Blood samples will be collected to determine the C24 of MK-1167.

    Time frame: 24 hours postdose on days 1, 8 and 16

  6. Time to reach maximum concentration (Tmax) of MK-1167 after Multiple Doses

    Blood samples will be collected to determine the Tmax of MK-1167.

    Time frame: Predose and at designated timepoints up to 24 hours postdose on days 1 and 8 and up to 600 hours postdose on day 16

  7. Apparent Clearance (CL/F) of MK-1167 after Multiple Doses

    Blood samples will be collected to determine the CL/F of MK-1167.

    Time frame: Predose and at designated timepoints up to 600 hours postdose on day 16

  8. Volume of Distribution (Vz/F) of MK-1167 at Steady State after Multiple Doses

    Blood samples will be collected to determine the Vz/F of MK-1167.

    Time frame: Predose and at designated timepoints up to 600 hours postdose on day 16

  9. Apparent Half Life (t½) of MK-1167 after Multiple Doses

    Blood samples will be collected to determine the t½ of MK-1167.

    Time frame: Predose and at designated timepoints up to 600 hours postdose on day 16

07

Study locations

1 site
  • California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International (Site 0001)
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in May 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 3, 2024
StartActual
Sep 18, 2023
Primary completionActual
May 8, 2024
CompletionActual
May 8, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625840
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Sep 18, 2023
Primary completion
May 8, 2024
Completion
May 8, 2024
Last update
Oct 3, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-1167

Start the discussion